CMR Surgical embarks on world-first paediatric clinical trial using Versius
CMR Surgical embarks on world-first paediatric clinical trial using Versius
- CMR Surgical has commenced the world’s first multicentre prospective clinical trial on the use of Versius in paediatric surgery
- Led by Mr Ewan Brownlee, Consultant Paediatric Urologist at the Southampton Children’s Hospital, part of the University Hospital Southampton NHS Foundation Trust, the prospective clinical study will assess the safety and efficacy of Versius, for use in urological procedures in paediatric surgery
- The clinical trial will take place over 3 clinical sites in the UK: Southampton Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, and Manchester University NHS Foundation Trust
Cambridge, United Kingdom. 1August 2024 07:00 (BST). CMR Surgical (CMR) – the global surgical robotics business – has today announced that it has commenced the first multicentre prospective clinical trial to assess the safety and efficacy of Versius for use in paediatric surgery. The trial is focusing on children and infants under the age of 18, undergoing a range of urological procedures with Versius including but not limited to robotic assisted pyeloplasty, ureteroureterostomy, nephrectomy and Mitrofanoff formation.
The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for robotic assisted minimal access surgery – a form of keyhole surgery. The uniquely small and modular design of Versius allows the system to be set up in a way that gives the surgeon optimal access in small, hard to reach spaces within an operating zone, while maintaining clear access to the patient for the anaesthetist and wider surgical team. The design of Versius provides the opportunity to support surgeons to conduct robotic-assisted paediatric surgery, and bring the benefits to more patients.
The multicentre prospective clinical trial will be performed in partnership with three clinical sites across the NHS. The Department of Paediatric Urology at Southampton Children’s Hospital – the primary site of the trial led by Mr Ewan Brownlee – has become the first to perform paediatric urology surgery with Versius in a clinical trial. The Department of Paediatric Urology at Royal Manchester Children's Hospital part of Manchester University NHS Foundation Trust, led by Mr David Keene; and Department of Paediatric Urology, and the Evelina London Children’s Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, led by Mr Pankaj Mishra make up the remaining sites taking part in the clinical trial.
Mark Slack, Co-founder and Chief Medical Officer at CMR Surgical commented: “We are delighted to begin the world’s first paediatric trials using Versius, in the UK. The small, modular design of Versius, and small instrument diameter provides an opportunity to be able to perform robotic-assisted surgery for the treatment of paediatric patients. We are committed to the responsible introduction of Versius across new specialties and we look forward to working with our partners as we undertake this clinical trial to ensure the safety and efficacy of Versius in paediatrics.”
Ewan Brownlee, Chief Investigator of the prospective clinical trial and Consultant Paediatric Surgeon at Southampton Children’s Hospital commented: “It is a privilege to be part of such a fantastic team here in Southampton; there is a huge list of people who have helped get us to this point of being able to start the first clinical trial using Versius in children and I am truly grateful to them all. It has also been a pleasure to be able to collaborate with excellent colleagues in Manchester and the Evelina and with CMR to be able to deliver this trial. We are excited for what feels like a landmark step forward in the development of paediatric robotic surgery.”
This study has been evaluated and approved by the West of Scotland Research Ethics Committee, the Medicines and Health Care Products Regulatory Agency (MHRA) and the Health Research Authorities (HRA). A total of 150 patients will participate in the trial and will include a thorough clinical follow up of their surgical outcomes, recovery and clinical outcomes for up to 1 year following the surgery.
Versius has now been used in over 23,000 surgical cases, with over 130 different surgical procedures undertaken across seven surgical specialties. The system is in routine use across urology, general surgery, gynaecology, colorectal surgery, and thoracic surgery. Versius is also being used in an ongoing clinical trial assessing the suitability of the system for use in transoral robotic surgery (TORS) at Liverpool University Hospitals NHS Foundation Trust’s (LUHFT) Aintree University Hospital.
— ENDS —
Media Contacts:
If you wish to see more, please contact CMR Surgical at:
Press Office, CMR Surgical
T +44(0) 1223 755801
Epressoffice@cmrsurgical.com
Notes to editors:
The Versius Surgical Robotic System
Versius resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.
Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.
But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.
About CMR Surgical Limited
CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.
Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.
Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.
References
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin